KR100358373B1 - 9-하이드록시리스페리돈지방산에스테르의수성현탁액 - Google Patents
9-하이드록시리스페리돈지방산에스테르의수성현탁액 Download PDFInfo
- Publication number
- KR100358373B1 KR100358373B1 KR10-1998-0703629A KR19980703629A KR100358373B1 KR 100358373 B1 KR100358373 B1 KR 100358373B1 KR 19980703629 A KR19980703629 A KR 19980703629A KR 100358373 B1 KR100358373 B1 KR 100358373B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- mixture
- active ingredient
- risperidone
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
Claims (13)
- 약제학으로 허용되는 담체가 물이고 활성 성분이 그 안에 현탁됨을 특징으로 하는; (1) 활성 성분으로서 치료 유효량의 하기 구조식의 9-하이드록시-리스페리돈 지방산 에스테르 또는 그의 염, 또는 입체 이성체 또는 입체 이성체 혼합물; 및 (2) 약제학적으로 허용되는 담체를 함유하는, 근육내 또는 피하 주사에 의해 투여하기에 데포(depot) 제제로서 적합한 약제학적 조성물:상기 식에서, R은 직쇄 C9-19알킬 라디칼을 나타낸다.
- 제1항에 있어서, R이 직쇄 C15(펜타데실) 쇄를 나타내고 활성 성분이 9-하이드록시리스페리돈 팔미테이트 에스테르인 조성물.
- 제1항에 있어서, 현탁화제 및 습윤제를 추가로 함유하는 조성물.
- 제3항에 있어서, 현탁화제가 나트륨 카복시메틸 셀루로즈이고 습윤제가 폴리소르베이트(polysorbate) 20인 조성물.
- 제1항에 있어서, 75 mPa.s 미만의 점도를 갖는 조성물.
- 제1항에 있어서, 조성물의 총 부피를 기초로 한 중량으로(a) 제1항에 따른 화합물 3 내지 20%(w/v);(b) 습윤제 0.05 내지 0.2%(w/v);(c) 현탁화제 0.5 내지 2%(w/v);(d) 방부제 2%(w/v) 이하; 및(e) 100%가 되게 하는 양의 물을 포함하는 조성물.
- 활성 성분을 담체와 밀접히 혼합시킴을 특징으로 하여 제1항 내지 제4항 제5항 및 제6항중 어느 한 항에 청구된 약제학적 조성물을 제조하는 방법.
- 제7항에 있어서,(a) 습윤제를 물과 함께 교반하고;(b) 방부제를 혼합물에 교반하면서 첨가하며;(c) 현탁화제를 혼합물에 교반하면서 분산시키고;(d) 활성 성분을 혼합물에 교반하면서 분산시키고, 이어서, 혼합물을 균질화시키는 단계들을 포함하는 방법.
- 정신분열증, 비정신분열증적 정신병, 신경변성 질환(예, 치매)과 관련된 행동 장애, 정신적 지체 및 자폐증에서의 행동 장애, 양극성 조증(bipolar mania), 우울증, 불안을 치료하는데 있어서 의약으로서 사용하기 위한 제1항 내지 제4항 제5항 및 제6항중의 어느 한 항에 따른 약제학적 조성물.
- 제3항에 있어서, 방부제, 완충제 및 등장화제, 및 이들의 혼합물로 구성된 그룹으로부터 선택된 첨가제를 추가로 함유하는 조성물.
- 제10항에 있어서, 방부제가 벤질알콜이고 등장화제가 만니톨 또는 인산염 완충액인 조성물.
- 제6항에 있어서, 등장화제를 추가로 함유하는 조성물.
- 제8항에 있어서, 단계 (c) 다음에 등장화제를 혼합물에 교반하면서 용해시키는 단계를 추가로 포함하는 방법.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96201429 | 1996-05-20 | ||
EP96201429.6 | 1996-05-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR19990067603A KR19990067603A (ko) | 1999-08-25 |
KR100358373B1 true KR100358373B1 (ko) | 2003-02-11 |
Family
ID=8224016
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-1998-0703629A KR100358373B1 (ko) | 1996-05-20 | 1997-05-12 | 9-하이드록시리스페리돈지방산에스테르의수성현탁액 |
Country Status (38)
Country | Link |
---|---|
US (1) | US6077843A (ko) |
EP (1) | EP0904081B1 (ko) |
JP (1) | JP3274687B2 (ko) |
KR (1) | KR100358373B1 (ko) |
CN (1) | CN1093762C (ko) |
AR (1) | AR007194A1 (ko) |
AT (1) | ATE208619T1 (ko) |
AU (1) | AU715572B2 (ko) |
BG (1) | BG62684B1 (ko) |
BR (1) | BR9706824B8 (ko) |
CA (1) | CA2236691C (ko) |
CY (2) | CY2270B1 (ko) |
CZ (1) | CZ291284B6 (ko) |
DE (2) | DE122011100027I1 (ko) |
DK (1) | DK0904081T3 (ko) |
EA (1) | EA000536B1 (ko) |
EE (1) | EE03594B1 (ko) |
ES (1) | ES2167745T3 (ko) |
FR (1) | FR11C0035I2 (ko) |
HK (1) | HK1017852A1 (ko) |
HR (1) | HRP970276B1 (ko) |
HU (2) | HU224025B1 (ko) |
ID (1) | ID16927A (ko) |
IL (1) | IL124551A (ko) |
LU (1) | LU91842I2 (ko) |
MX (1) | MX9804816A (ko) |
MY (1) | MY126302A (ko) |
NO (2) | NO315931B1 (ko) |
NZ (1) | NZ330369A (ko) |
PL (1) | PL188309B1 (ko) |
PT (1) | PT904081E (ko) |
SI (1) | SI0904081T1 (ko) |
SK (1) | SK284013B6 (ko) |
TR (1) | TR199800923T2 (ko) |
TW (1) | TW487572B (ko) |
UA (1) | UA61898C2 (ko) |
WO (1) | WO1997044039A1 (ko) |
ZA (1) | ZA974331B (ko) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA72189C2 (uk) * | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
AU753278B2 (en) * | 1998-02-25 | 2002-10-10 | Abbott Laboratories | Butorphanol sustained release formulations |
AU5489299A (en) * | 1998-08-18 | 2000-03-14 | Sepracor, Inc. | Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine |
ATE313319T1 (de) | 1999-03-31 | 2006-01-15 | Janssen Pharmaceutica Nv | Vorgelatinierte stärke in einer formulierung mit gesteuerter freigabe |
US6495164B1 (en) * | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
SK2982003A3 (en) * | 2000-08-14 | 2004-10-05 | Teva Pharma | Preparation of risperidone |
US7666445B2 (en) * | 2000-10-20 | 2010-02-23 | The Trustees Of The University Of Pennsylvania | Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use |
GB0216416D0 (en) * | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
US20050232995A1 (en) | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
ATE373472T1 (de) * | 2002-07-29 | 2007-10-15 | Alza Corp | Verfahren und dosierformen für die kontrollierte abgabe von paliperidon |
GB0322994D0 (en) * | 2003-10-01 | 2003-11-05 | Novartis Ag | Organic compounds |
ES2315721T5 (es) | 2003-10-23 | 2012-08-24 | Otsuka Pharmaceutical Co., Ltd. | Formulación de aripiprazol inyectable estéril de liberación controlada y procedimiento |
US8221778B2 (en) * | 2005-01-12 | 2012-07-17 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
US8329203B2 (en) * | 2004-01-12 | 2012-12-11 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
EP1711124A4 (en) * | 2004-01-12 | 2011-06-01 | Univ Pennsylvania | LONG-TERM RELEASE PREPARATIONS AND METHODS OF USE THEREOF |
ES2245252B1 (es) * | 2004-06-15 | 2007-03-01 | Farmalider, S.A. | Solucion acuosa de risperidona para administracion oral. |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
WO2006114384A1 (en) | 2005-04-25 | 2006-11-02 | Janssen Pharmaceutica N.V. | Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester |
PL116330U1 (en) | 2005-10-31 | 2007-04-02 | Alza Corp | Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation |
AU2007284759B2 (en) | 2006-08-09 | 2010-10-28 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies |
DK2154138T3 (en) * | 2007-04-19 | 2015-11-02 | Youxin Li | Novel compounds for the treatment of psychotic disorders, methods of preparation and uses thereof |
CN105688191A (zh) | 2007-04-23 | 2016-06-22 | 精达制药公司 | 促胰岛素释放肽的混悬制剂及其应用 |
US20090076035A1 (en) * | 2007-09-15 | 2009-03-19 | Protia, Llc | Deuterium-enriched paliperidone |
CN105560176A (zh) * | 2007-12-19 | 2016-05-11 | 詹森药业有限公司 | 与长效注射用帕潘立酮酯相关的给药方案 |
US20090209757A1 (en) * | 2008-01-10 | 2009-08-20 | Santiago Ini | Processes for the preparation and purification of paliperidone palmitate |
DK2240155T3 (da) | 2008-02-13 | 2012-09-17 | Intarcia Therapeutics Inc | Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler |
ES2809178T5 (es) | 2008-09-04 | 2024-04-29 | Amylin Pharmaceuticals Llc | Formulaciones de liberación sostenida que usan portadores no acuosos |
MX352878B (es) | 2009-09-28 | 2017-12-13 | Intarcia Therapeutics Inc | Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco. |
NZ599558A (en) | 2009-10-30 | 2014-09-26 | Janssen Pharmaceutica Nv | Dosing regimen associated with long-acting injectable paliperidone esters |
US20120259116A1 (en) * | 2009-12-17 | 2012-10-11 | Rajiv Kumar | Novel Process for the Preparation of Paliperidone |
TWI577377B (zh) | 2010-09-16 | 2017-04-11 | Viiv醫療保健公司 | 醫藥組合物 |
CN103249416B (zh) | 2010-10-18 | 2019-06-04 | 大日本住友制药株式会社 | 注射用缓释制剂 |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
WO2012164582A1 (en) | 2011-05-31 | 2012-12-06 | Ramamohan Rao Davuluri | Preparation of 3-[2-[4-((6-fluoro-1, 2-benzisoxazol-3-yl)-l-piperidinyl)-6, 7, 8, 9-tetrahydro-9-hydroxy-2-methyl-4h-pyrido[ 1, 2-a]-pyrimidin-4-one (paliperidone) and paliperidone palmitate. |
WO2013046225A2 (en) * | 2011-08-10 | 2013-04-04 | Glenmark Generics Limited | Process for the preparation of paliperidone palmitate |
CN102993200B (zh) * | 2011-09-10 | 2016-02-03 | 鲁翠涛 | 帕潘立酮氨基酸酯及其制备方法 |
WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
US10525057B2 (en) | 2013-09-24 | 2020-01-07 | Otsuka Pharmaceutical Co., Ltd. | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
LT3744326T (lt) | 2015-04-07 | 2023-12-27 | Janssen Pharmaceutica Nv | Dozavimo schema praleistoms ilgai veikiančių injekcinių paliperidono esterių dozėms |
CN113598842A (zh) | 2015-06-03 | 2021-11-05 | 因塔西亚制药公司 | 植入物放置和移除*** |
MX2018014016A (es) | 2016-05-16 | 2019-08-01 | Intarcia Therapeutics Inc | Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos. |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
EP3565580B1 (en) | 2017-01-03 | 2024-03-06 | i2o Therapeutics, Inc. | Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel |
FI4025187T3 (fi) | 2020-11-30 | 2024-02-13 | Janssen Pharmaceutica Nv | Pitkävaikutteisiin injektoitaviin paliperidoniformulaatioihin liittyviä annosteluohjelmia |
WO2022111859A1 (en) | 2020-11-30 | 2022-06-02 | Janssen Pharmaceutica Nv | Dosing regimens associated with extended release paliperidone injectable formulations |
KR20230116836A (ko) | 2020-11-30 | 2023-08-04 | 얀센 파마슈티카 엔.브이. | 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법 |
JP2023551007A (ja) | 2020-11-30 | 2023-12-06 | ヤンセン ファーマシューティカ エヌ.ベー. | パルミチン酸パリペリドン製剤の再懸濁を確実にする方法 |
HUP2100259A1 (hu) | 2021-07-07 | 2023-01-28 | Richter Gedeon Nyrt | Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények |
WO2023021008A1 (en) | 2021-08-20 | 2023-02-23 | Janssen Pharmaceutica Nv | Dosing regimens associated with extended release paliperidone injectable formulations |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5254556A (en) * | 1988-11-07 | 1993-10-19 | Janssen Pharmaceutica N.V. | 3-piperidinyl-1,2-benzisoxazoles |
US5158952A (en) * | 1988-11-07 | 1992-10-27 | Janssen Pharmaceutica N.V. | 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use |
CA2000786C (en) * | 1988-11-07 | 1999-01-26 | Cornelus G. M. Janssen | 3-piperidinyl-1,2-benzisoxazoles |
TW376319B (en) * | 1993-04-28 | 1999-12-11 | Janssen Pharmaceutica Nv | Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine |
US5650173A (en) * | 1993-11-19 | 1997-07-22 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradable microparticles containing a biologically active agent |
EP2275089A1 (en) * | 1993-11-19 | 2011-01-19 | Alkermes Controlled Therapeutics, Inc. | Preparation of biodegradable microparticles containing a biologically active agent |
KR100354270B1 (ko) * | 1993-11-19 | 2003-02-11 | 알커메스 컨트롤드 테라포이틱스 인코퍼레이티드 Ii | 마이크로캡슐화된3-피페리디닐-치환된1,2-벤즈이속사졸및1,2-벤즈이소티아졸 |
MX9709451A (es) * | 1995-06-06 | 1998-02-28 | Hoechst Marion Roussel Inc | Derivados de benzisoxazol e indazol como agentes antipsicoticos. |
US5792477A (en) * | 1996-05-07 | 1998-08-11 | Alkermes Controlled Therapeutics, Inc. Ii | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
-
1997
- 1997-05-01 TW TW086105768A patent/TW487572B/zh not_active IP Right Cessation
- 1997-05-12 EE EE9800136A patent/EE03594B1/xx active Protection Beyond IP Right Term
- 1997-05-12 SI SI9730272T patent/SI0904081T1/xx unknown
- 1997-05-12 SK SK620-98A patent/SK284013B6/sk not_active IP Right Cessation
- 1997-05-12 NZ NZ330369A patent/NZ330369A/xx not_active IP Right Cessation
- 1997-05-12 EP EP97923912A patent/EP0904081B1/en not_active Expired - Lifetime
- 1997-05-12 JP JP54150097A patent/JP3274687B2/ja not_active Expired - Lifetime
- 1997-05-12 AU AU29559/97A patent/AU715572B2/en not_active Expired
- 1997-05-12 PT PT97923912T patent/PT904081E/pt unknown
- 1997-05-12 HU HU9901319A patent/HU224025B1/hu active Protection Beyond IP Right Term
- 1997-05-12 IL IL12455197A patent/IL124551A/xx not_active IP Right Cessation
- 1997-05-12 AT AT97923912T patent/ATE208619T1/de active
- 1997-05-12 WO PCT/EP1997/002504 patent/WO1997044039A1/en active IP Right Grant
- 1997-05-12 BR BRPI9706824-1B8A patent/BR9706824B8/pt not_active IP Right Cessation
- 1997-05-12 KR KR10-1998-0703629A patent/KR100358373B1/ko active IP Right Review Request
- 1997-05-12 CZ CZ19981401A patent/CZ291284B6/cs not_active IP Right Cessation
- 1997-05-12 DE DE201112100027 patent/DE122011100027I1/de active Pending
- 1997-05-12 TR TR1998/00923T patent/TR199800923T2/xx unknown
- 1997-05-12 DK DK97923912T patent/DK0904081T3/da active
- 1997-05-12 CA CA002236691A patent/CA2236691C/en not_active Expired - Lifetime
- 1997-05-12 DE DE69708284T patent/DE69708284T2/de not_active Expired - Lifetime
- 1997-05-12 ES ES97923912T patent/ES2167745T3/es not_active Expired - Lifetime
- 1997-05-12 EA EA199800531A patent/EA000536B1/ru not_active IP Right Cessation
- 1997-05-12 CN CN97191494A patent/CN1093762C/zh not_active Expired - Lifetime
- 1997-05-12 US US09/180,659 patent/US6077843A/en not_active Expired - Lifetime
- 1997-05-12 PL PL97327995A patent/PL188309B1/pl unknown
- 1997-05-19 ZA ZA974331A patent/ZA974331B/xx unknown
- 1997-05-19 MY MYPI97002172A patent/MY126302A/en unknown
- 1997-05-19 ID IDP971649A patent/ID16927A/id unknown
- 1997-05-19 AR ARP970102112A patent/AR007194A1/es active IP Right Grant
- 1997-05-20 HR HR970276A patent/HRP970276B1/xx not_active IP Right Cessation
- 1997-12-05 UA UA98052747A patent/UA61898C2/uk unknown
-
1998
- 1998-04-30 NO NO19981984A patent/NO315931B1/no not_active IP Right Cessation
- 1998-05-12 BG BG102443A patent/BG62684B1/bg unknown
- 1998-06-15 MX MX9804816A patent/MX9804816A/es unknown
-
1999
- 1999-07-10 HK HK99102949A patent/HK1017852A1/xx not_active IP Right Cessation
-
2002
- 2002-04-25 CY CY0200021A patent/CY2270B1/xx unknown
-
2011
- 2011-07-20 LU LU91842C patent/LU91842I2/fr unknown
- 2011-08-18 CY CY2011011C patent/CY2011011I2/el unknown
- 2011-08-18 HU HUS1100013C patent/HUS1100013I1/hu unknown
- 2011-08-29 NO NO2011015C patent/NO2011015I2/no unknown
- 2011-09-02 FR FR11C0035C patent/FR11C0035I2/fr active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100358373B1 (ko) | 9-하이드록시리스페리돈지방산에스테르의수성현탁액 | |
US8293765B2 (en) | Injectable depot formulation comprising crystals of iloperidone | |
EP2020243B1 (en) | Topically applicable pharmaceutical preparation | |
EP2897592B1 (en) | Pharmaceutical compositions having improved storage stability | |
SK6882000A3 (en) | Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters | |
JP2010235622A (ja) | プロポフォールの水溶性プロドラッグの水ベースの薬学的製剤 | |
KR20150114505A (ko) | 불용성 코르티코스테로이드 및 수용성 코르티코스테로이드를 포함하는 약학적 제형 | |
US20230255960A1 (en) | Aripiprazole injectable suspension formulation having prolonged shelf life | |
US10603278B2 (en) | Microspheres containing anthelmintic macrocyclic lactones | |
US20220370359A1 (en) | Fulvestrant pharmaceutical composition, preparation method therefor, and application thereof | |
KR20060012030A (ko) | 디아제팜을 함유하는 경비 마이크로에멀젼 | |
JPH05501541A (ja) | 繁殖力増強 | |
SK847488A3 (en) | Process for producing of cyclosporine a | |
MXPA00004793A (en) | Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
A101 | Application to extend term of patent right by permit | ||
FPAY | Annual fee payment |
Payment date: 20120924 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20130924 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20140923 Year of fee payment: 13 |
|
J204 | Request for invalidation trial [patent] | ||
J204 | Request for invalidation trial [patent] | ||
FPAY | Annual fee payment |
Payment date: 20150918 Year of fee payment: 14 |
|
J121 | Written withdrawal of request for trial | ||
FPAY | Annual fee payment |
Payment date: 20160921 Year of fee payment: 15 |
|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2015100003000; TRIAL DECISION FOR INVALIDATION REQUESTED 20150429 Effective date: 20170904 |
|
FPAY | Annual fee payment |
Payment date: 20170919 Year of fee payment: 16 |
|
FPAY | Annual fee payment |
Payment date: 20180918 Year of fee payment: 17 |
|
FPAY | Annual fee payment |
Payment date: 20190917 Year of fee payment: 18 |